Form 4: 4D Molecular Therapeutics Director Jacob Chacko Granted Significant Stock Options

Jacob Chacko, a Director at 4D Molecular Therapeutics, Inc. (FDMT), was granted 22,500 stock options with an exercise price of $4.15 as part of the company's non-employee director compensation program.

Summary

• Jacob Chacko, a Director of 4D Molecular Therapeutics, Inc. (FDMT), was granted 22,500 stock options.
• The stock options have an exercise price of $4.15 per share.
• The grant date for these options was June 17, 2025.
• The options were automatically granted pursuant to the terms of the Company's non-employee director compensation program.
• The vesting schedule dictates that 1/3 of the total shares will vest on June 17, 2026, with the remaining shares vesting in equal monthly installments thereafter, subject to Mr. Chacko's continued service to the Issuer, until fully vested on June 17, 2028.
• Additionally, the stock options will vest in full upon the consummation of a Change in Control, as defined in the 2020 Incentive Award Plan.
• The expiration date for these stock options is June 16, 2035.

Sentiment

Score: 7

Explanation: The document reports a standard and expected compensation event for a director, which is generally positive as it aligns interests. There are no negative surprises or significant financial impacts beyond the routine compensation.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, as the options gain value only if the company's stock price increases above the exercise price.
• This transaction is part of a standard non-employee director compensation program, indicating a structured approach to incentivizing and retaining key board members.

Negatives

• No direct negatives are identified in this specific Form 4 filing, as it reports a routine compensation grant.

Risks

• The value of the granted stock options is directly tied to the future market performance of 4D Molecular Therapeutics' common stock. If the stock price does not exceed the $4.15 exercise price, the options may expire worthless.
• The vesting of the options is contingent upon Jacob Chacko's continued service to the company. If his service ceases before the full vesting period, unvested options could be forfeited.

Future Outlook

The document primarily reports a past transaction (option grant) and outlines future vesting dates. It implies a continued commitment from the director to the company's long-term performance, as the options vest over several years and align his interests with future stock price appreciation.

Management Comments

• The stock options were automatically granted pursuant to the terms of the Company's non-employee director compensation program.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, specifically the grant of stock options to a non-employee director. Such compensation is a common practice across the biotechnology and broader corporate sectors, serving as a key incentive to attract, retain, and align the interests of board members with long-term shareholder value creation, particularly given the often lengthy and capital-intensive development cycles in the biopharmaceutical industry.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard practice across the biotechnology and broader corporate landscape, aiming to align director incentives with shareholder value creation.
• The vesting schedule, with a multi-year period and accelerated vesting upon a change in control, is typical for equity compensation plans designed to encourage long-term commitment and provide liquidity events.
• The exercise price being set at the market price on the grant date (implied by the nature of the grant and lack of other price information) is also a common practice for incentive stock options.

Stakeholder Impact

• **Shareholders:** The grant of stock options aligns the director's interests with shareholder value creation, as the options become more valuable if the company's stock price increases. This incentivizes the director to make decisions that benefit long-term stock performance.
• **Employees:** No direct impact on general employees, but it reinforces the company's use of equity-based compensation as a retention and incentive tool for key personnel.

Next Steps

• Continued service of Jacob Chacko to 4D Molecular Therapeutics, Inc. to ensure vesting of options.
• Monitoring of 4D Molecular Therapeutics' stock performance relative to the $4.15 exercise price.
• Future Form 4 filings will be required for any subsequent transactions by Jacob Chacko.

Key Dates

Keywords

4D Molecular Therapeutics, FDMT, Jacob Chacko, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Compensation, Biotechnology